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ABSTRACT 
 
 
In Multiple Sclerosis patients, previous experiments have determined the 
structure, potential function, and regulation of the oxidative damage resistance protein 
nuclear receptor coactivator-7 alternate start (NCOA7-AS) through induction with 
Interferon-β (IFN-β). However, the subcellular localization of NCOA7-AS remains 
unknown. In this project, the localization will be determined by fusing GFP to NCOA7-
AS, expressing the fusion protein in HT1080 and HeLa cells, and using fluorescence 
microscopy. Cells will also be treated with IFN-β to see if this alters NCOA7-AS 
localization. The GFP microscopy data indicate that NCOA7-AS localization is diffuse in 
cells with no clear subcellular localization, and that addition of IFN-β does not alter the 
localization. 
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BACKGROUND 
 
 
 
Oxidation Resistance in Multiple Sclerosis 
 Multiple Sclerosis (MS) is an inflammatory disease that occurs when the myelin 
sheathes surrounding the spinal cord and axons in the brain deteriorates, causing 
demyelination, and leading to a number of detrimental symptoms (Compston and Coles, 
2008). MS causes the body’s immune system to damage the myelin sheathes of axons, 
which leads to the loss of the ability of axons to send and conduct action potentials 
(Compston and Coles, 2008). This damage occurs when T cells that normally recognize 
foreign antigens enter the brain though disruptions in the blood brain barrier, recognize 
myelin as an antigenic agent, and begin to attack it (Figure-1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure-1: Pathogenesis of Multiple Sclerosis.  (Baranzini and Hauser, 2002). 
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The process of immune cells reacting with self antigens is known as molecular 
mimicry (Wucherpfennig and Strominger, 1995). This triggers an inflammatory response, 
activating other immune cells and factors such as antibodies and cytokines, which leads 
to further damage to the blood brain barrier. In MS, possible targets of the immune 
response include myelin basic protein (MBP) and proteolipid protein (PLP), though 
recent data suggests myelin lipids may also be a target (Ho et al., 2012).  
MS is responsible for a number of neurological symptoms, and physical and 
cognitive disabilities, such as ataxia, hypoesthesia, chronic pain, optic neuritis, and 
depression (Rosati, 2001). The cause of MS is believed to be a combination of genetic, 
environmental, and infectious factors. In the case of genetic factors, differences in the 
human leukocyte antigen (HLA) system, a set of alleles DR15 and DQ6 located on 
chromosome-6 that forms the major histocompatibility complex in humans, have been 
shown to increase the probability of contracting MS (Compston and Coles, 2008). 
 Another affliction caused by MS, as seen in many other neurological disorders, is 
oxidative DNA damage caused by oxidative free radicals. A healthy human body has a 
functioning antioxidant system that prevents damage or loss due to free radicals. 
However, imbalances of antioxidants or overproduction of oxidative free radicals due to 
neurodegeneration can lead to irreparable oxidative damage.  This oxidative damage 
causes lesions in DNA and inactivation of proteins, inflammation, tissue damage, and 
possibly cellular apoptosis (Uttara et al., 2009). Recently, work has been conducted to 
identify a number of novel proteins that function to resist or repair oxidative damage 
caused by free radicals (Durand et al., 2007; Yu et al., submitted for publication). These 
oxidative resistance proteins show potential to possibly treat, or even prevent, oxidative 
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DNA damage resulting from neurodegenerative diseases, including MS.  Results of this 
potential therapeutic work will be discussed further in other sections of this paper. 
 
OXR Domain and Eukaryotic Oxidation Resistance Proteins 
 Reactive oxygen species (ROS) have been shown to cause oxidative damage to 
DNA. There are a number of cellular processes that prevent lethal effects of ROS. These 
protective proteins fall into two main categories, those that prevent oxidative DNA 
damage from occurring, and those that repair damage caused by ROS. One gene that 
encodes an oxidative resistance protein is OXR1.  This gene can be induced by oxidative 
stress and heat, and its protein product localizes to mitochondria. OXR genes are 
conserved among all sequenced eukaryotes, ranging from yeast to humans (Durand et al., 
2007).  
 Recently, experiments were performed to determine whether a second human 
gene, nuclear receptor coactivator 7 (NCOA7), that shares many similarities with OXR1, 
could function to prevent oxidative mutagenesis (Durand et al., 2007). This work also 
determined the structure of NCOA7 and its regulation (Durand et al., 2007). NCOA7 was 
able to reduce the DNA damaging effects of ROS.  The oxidative resistance function of 
NCOA7 appears to reside in its carboxyl-terminal domain, which has similarities to 
OXR1. The experiments also determined that NCOA7 is constitutively expressed in 
human cells, and is not induced by oxidative stress, suggesting that the protein product of 
NCOA7 functions in oxidative resistance rather than repair (Durand et al., 2007). 
NCOA7 protein was also found to associate with the estrogen receptor, rather than be 
induced by stress, like OXR1.  DNA damage due to oxidation has been shown to result as 
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a byproduct of estradiol metabolism (Seacat et al., 1997). This suggests that NCOA7 
functions to lessen oxidative DNA damage that results from estrogen metabolism. 
 The structure and regulation of an isoform of the NCOA7 gene was recently 
discovered (Yu et al., submitted for publication). This variant is known as nuclear 
receptor coactivator 7-alternate start (NCOA7-AS). NCOA7-AS is found to have 
homology with the C-terminal region of NCOA7 gene, thus sharing similarities with 
OXR1 (Yu et al., submitted for publication). NCOA7-AS contains exons 11-15 of full 
length NCOA7, but it begins with a new exon (10a) which is encoded between exons 10 
and 11 (Figure-2). Exon 9 of NCOA7, like exon 8 of OXR1, is likely responsible for its 
antioxidant function. Therefore, exon 10a may replace the function of exon 9 for 
oxidative resistance. Previous work discussed later in this report demonstrates the 
antioxidant activity of NCOA7-AS, further supporting this hypothesis. NCOA7-AS also 
varies from NCOA7 in that it lacks the estrogen-binding domain found in exon 8 (Shao et 
al., 2002). This suggests that interacting with the estrogen-estrogen receptor complex is 
exclusive to NCOA7 and its longer forms, but not to NCOA7-AS (Yu et al., submitted). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Structures of NCOA7, NCOA7-AS, and OXR1. (A) Gene alignments of 
NCOA7, NCOA7-AS, and OXR1. (B) Amino acid sequence of NCOA7-AS, underlined 
sequence indicates the sequence coded by exon 10a (Yu et al., submitted). 
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 The experiments also determined that NCOA7-AS is regulated by, and dependent 
on, the Janus Kinase (JAK) and Signal Transducers and Activators of Transcription 
(STAT) pathway (Yu et al., submitted for publication). Mutations in key genes of the 
JAK-STAT regulatory pathway blocked the induction of NCOA7-AS.  Induction of 
NCOA7-AS requires a functional IFN-receptor, JAK1, and STAT2 genes (Yu et al., 
submitted for publication). This differs from full length NCOA7, which is constitutively 
expressed and whose nuclear localization is stimulated by interactions with the estrogen 
receptor (Durand et al., 2007). 
 
Protein Subcellular Localization 
 Cells of eukaryotic organisms are subdivided into functionally and 
morphologically distinct compartments. The compartmental location, or lack thereof, 
where a particular protein is found is defined as its subcellular localization (Schuler, 
2004). Determining the subcellular localization of a protein is necessary to better 
understand its function.  
One method that can be utilized to determine localization is immunostaining. This 
procedure involves endogenously tracking a protein in cells by inserting an antibody that 
identifies the protein of interest. A secondary fluorescent antibody that identifies the 
primary protein antibody is then added to observe the localization of the native protein 
(Coons et al., 1941). Bioinformatic models can also be used to predict localization (Scott 
et al., 2005). Another method that can be used to determine localization is ligating the 
gene that encodes the protein of interest with a fluorescent tagged expression vector, 
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inserting the fusion vector into cells, allowing the fusion protein to become expressed, 
and using fluorescence microscopy to observe protein localization (Huh et al., 2003).  
 The protein product of the OXR1 gene has been found to localize to the 
mitochondria of cells. Recently work has also been able to determine the localization of 
protein NCOA7 (Durand et al., 2007). Immunofluorescence assays showed that NCOA7 
shows clear subcellular localization in the nucleus of human cells stimulated by estrogen 
(Durand et al., 2007). This differs from the mitochondrial localization of OXR1 (Elliot 
and Volkert, 2004), suggesting that NCOA7 may encode the nuclear counterpart of the 
OXR1 protein. The subcellular localization of NCOA7-AS, the alternate start form of 
NCOA7, is still undetermined. 
 
Interferon-β Induction of NCOA7 
 Type I interferons are widely conserved proteins, and play an integral role in 
organizing antiviral responses (Mogensen et al., 1999). The common structure of 
interferons is a compact helical protein that reacts with heteromeric cell surface receptors 
present on mammalian cells (Stark et al., 1998). Over time, evolution has resulted in a 
defined family of IFNs, including IFNβ, that are only expressed in certain cell types. The 
reason IFNs have evolved is most likely due to the changes in adaptive immune 
responses, innate responses to cell proliferation, and proliferation of cells. Because of 
this, IFNs are able to induce a large number of varying genes (Stark et al., 1998). 
 IFNs are very useful in treating a number of human diseases, including Multiple 
Sclerosis (Croze et al., 2009). IFN works as a treatment for MS by shifting the Th1/Th2 
response, stabilization of the blood brain barrier, and promoting the differentiation of 
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oligodendrocytes, brain cells that produce myelin to insulate axons (Arnason et al., 1996). 
Previous work showed that patients that suffer from neurological diseases often accrue 
neuronal damage due to increased reactive oxygen species (ROS). Thus, it is possible that 
the tissue damage occurring in MS patients by an inflammatory response results from an 
overabundance of reactive oxygen species (Melo et al., 2011).  
 One function of IFN is to repair the tissue damage caused by oxidative stress due 
to ROS (Croze et al., 2009). Recently, experiments showed that IFNβ-1b increased the 
expression of NCOA7-AS (discussed above) (Yu et al., submitted for publication). The 
experiments also determined the mechanism of regulation for NCOA7-AS, its structure, 
and its ability to function as an oxidative repair protein relative to the regular full length 
NCOA7 (Yu et al., submitted for publication). 
 NCOA7 exon expression measurements using exon microarrays were made using 
peripheral blood mononucleocytes (PBMCs) taken at 0, 4, and 18 hours from seven 
patients exhibiting the relapsing-remitting form of MS that were treated at time 0 with 
Betaseron, a form of IFNβ-1b used to treat MS patients (Figure-3). The results showed 
that exons 2, 7, 8, 9, and 10 are not expressed at elevated levels after Betaseron treatment, 
while exons 11, 12, and 15 show strong induction. This shows that three exons of 
NCOA7-AS are strongly induced by Betaseron (IFNβ-1b). PBMCs of three healthy 
volunteers and primary human fetal brain cells were also treated with Betaseron to 
examine the induction of NCOA7-AS. The combined results showed that NCOA7-AS is 
induced by IFNβ-1b in PBMCs of MS patients, healthy individuals, and cells obtained 
from the CNS (Yu et al., submitted for publication). 
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Figure 3: NCOA7 Exon Expression Measurements in IFN-Treated MS Patients 
Using Exon Microarrays.  XRAY v2.63 Analysis of Human Exon 1.0 ST GeneChip® 
Data Using mRNA Collected from MS Patients Injected with Betaseron (IFNβ-1b). 
NCOA7-AS exons induced by Betaseron are shown from exons 10-16 (Yu et al., 
submitted for publication). 
 
 
 
Human HT1080 fibrosarcoma cells express IFNAR1 and IFNAR2 receptors 
which interact with IFNβ-1b (Der et al., 1998). HeLa cells, a cell line used in this project 
but not in the work being discussed in this section, have been shown to interact with 
interferon as well (West and Balioni, 1979). NCOA7-AS shows strong induction in this 
cell line, as well as some neuroblastoma cell lines (Figures 4A and 4B). Previous work 
also shows that NCOA7 is not induced in response to oxidative stress (Durand et al., 
2007). HT1080 cells were treated with varying doses of hydrogen peroxide, and levels of 
NCOA7-AS mRNA were measured after 4 hours. The data showed that NCOA7-AS is 
not induced by treatment with H2O2 (Figure 4C). 
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Figure 4: IFN Induction of NCOA7-AS in HT1080 and Neuroblastoma Cell Lines, 
and Non-Response to H2O2 Treatment. (A) Induction of NCOA7-AS in HT1080 
fibrosarcoma cells. (B) A probe detecting NCOA7-AS in SHSY5Y and LAN6 
neuroblastoma cells. (C) HT1080 cells treated with indicated concentrations of H2O2 or 
IFNβ-1b for 4 hours before mRNA isolation (Yu et al., submitted for publication). 
 
 
 
Previous studies also showed that NCOA7-AS can serve as an oxidative damage 
resistance protein through expression in E. coli with mutations in mutM and mutY. Wild 
type mutM and mutY normally prevent GC->TA transversions (Michaels et al., 1992; 
Wang et al., 2004; Volkert et al., 2008). The strain also carries a lacZ allele, which 
reverts to Lac
+
 in the presence of GC->TA transversions and acts as an oxidative DNA 
damage reporter (Michaels et al., 1992; Michaels and Miller, 1992; Wang et al., 2004; 
Volkert et al., 2008). Colonies carrying expression plasmid pTrc99A with either a full 
length NCOA7 or NCOA7-AS insert show suppression of oxidative mutagenesis, while 
colonies with the pTrc99A vector only show high levels of transversion mutations. This 
shows that both proteins exhibit strong oxidative damage prevention activity and thus 
have an antioxidant function (Yu et al., submitted for publication). As mentioned 
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previously, work also demonstrated that expression of NCOA7-AS is dependent on the 
JAK-STAT pathway (Yu et al., submitted for publication). However, the subcellular 
localization of the NCOA7-AS protein is still undetermined. In this project, GFP will be 
fused with NCOA7-AS to determine its cellular location and whether the localization is 
altered by treating the cells with IFNβ-1b. 
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PROJECT PURPOSE 
 
 This project was performed to determine the subcellular localization of NCOA7-
AS protein in cells. Previous studies showed that NCOA7-AS can be induced by 
Interferon-β, and determined the localization of other forms of the NCOA7 gene. But the 
location of NCOA7-AS remains unknown.  Determining the localization of NCOA7-AS 
would help to further understand the gene’s role in cellular oxidative resistance, and 
provide further insight into its presence and function in patients with Multiple Sclerosis. 
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METHODS 
 
 
DH5α Strains, Plasmids, and Primers 
 
 
Table 1: Table of Strains Used in this Project 
E. coli Strain Number Cell Type and Plasmid Insert 
MV7034 DH5α + pMV1559 
MV7035 DH5α + pMV1560 
 
 
Table 2: Table of Plasmids Used in this Project 
Plasmid Name Vector Insert 
pMV1559 pEGFP-N1 NCOA7-as 
pMV1560 pEGFP-N1 NCOA7-as 
 
 
 
Table 3: Table of Primers Used in this Project 
Primer 
Number 
Primer Name Sequence (5’-3’) 
Use 
609 609 N1 prF 
GCGCGAATTCATGAGAGGCCAAA
GATTACCCTT 
PCR Product 
restrictions of 
NCOA7-as and 
pEGFP-N1 
610 610 N1 prR 
CGCGACCGGTCGATCAAATGCCCA
CACCTCCAG 
611 611 C1 prF 
GCGCTCCGGAAGAGGCCAAAGAT
TACCCTTGGA 
PCR Product 
restrictions of 
NCOA7-as and 
pEGFP-C1 
612 612 C1 prR 
GCGCGAATTCTCAATCAAATGCCC
ACACCT 
613 613 pEGFPN1 seq TACCGGACTCAGATCTCGAGCTCA Clone 
Sequencing of 
plasmid 
pMV1559 
614 614 pEGFPN1 seq CAGCTCCTCGCCCTTGCTCACCAT 
615 615 pEGFPC1 seq GATCACTCTCGGCATGGACGAGCT Clone 
Sequencing of 
plasmid 
pMV1560 
616 616 pEGFPC1 seq GGATCCCGGGCCCGCGGTACCGTC 
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Ligation of NCOA7-AS and pEGFP 
PCR 
 The NCOA7-AS gene used for this project was procured from a variant of the 
gene with a silent mutation at codon 40 (base pair 120) that is routinely used in the 
Volkert lab. The silent mutation (AGC  AGT) does not affect the protein sequence, as 
both sequences encode serine at that location. The plasmid expression vector used was 
pEGFP, isolated from E. coli strains using Qiagen’s QIAprep® Miniprep kit. Features of 
these vectors include a constitutive CMV promoter, a kanamycin resistance gene, and an 
EGFP tag. 
 PCR products were created to have two copies of NCOA7-AS to ligate with 
pEGFP, one which attached NCOA7-AS to the N-terminus, and the other at the C-
terminus of EGFP. The N-terminus product was created using primers 609 
(GCGCGAATTCATGAGAGGCCAAAGATTACCCTT) and 610 
(CGCGACCGGTCGATCAAATGCCCACACCTCCAG). The PCR product contained 
an EcoRI restriction site at the beginning of the coding strand of the gene and an AgeI 
site at the end of the template strand. These restriction sites were also found in the 
pEGFP-N1 vector. The C-terminus product was created using primers 611 
(GCGCTCCGGAAGAGGCCAAAGATTACCCTTGGA) and 612 
(GCGCGAATTCTCAATCAAATGCCCACACCT). This PCR product contained a 
BspEI restriction site at the beginning of the coding strand, and an EcoRI site at the end 
of the template strand. These restriction sites are also present in the pEGFP-C1 vector, at 
an appropriate position to produce a EGFP fusion protein. All PCR reactions were 
performed using Taq Polymerase (New England Biolabs). 
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 The N-terminus PCR product and pEGFP-N1 were double-digested with EcoRI 
and AgeI in New England Biolabs’ reaction buffer 1 at 37°C for 3 hours. The C-terminus 
PCR product and pEGFP-N1 were double-digested with BspEI and EcoRI in New 
England Biolabs’ reaction buffer 3 at 37°C for 3 hours. Samples of each restriction 
digestion were then run on an electrophoresis gel, and band lengths were observed to 
determine the effectiveness of the digestions. Since the gel showed bands of expected 
sizes for each product, the restriction products were then purified using Qiagen’s 
QIAprep
® 
Miniprep kit. 
 
Ligations and Transformations 
 The NCOA7-AS and pEGFP digests were ligated using New England Biolabs’ 
Quick Ligase kit. The ligation created two clones, one that was a C-terminus fusion 
(EGFP-NCOA7-AS) and the other was an N-terminus fusion (NCOA7-AS-EGFP). 
DH5α cells were transformed with the resulting ligation products, plated on LB+Kan 
plates, and incubated for 24 hours. The transformations yielded five colonies containing 
the C-terminus fusion, and five with the N-terminus fusion. These colonies were 
inoculated into LB-KAN broth, and the plasmid DNA was purified after 24 hours of 
incubation. The C-terminal fusion vector DNA was then digested using BspEI and 
EcoRI, and the N-terminal fusion vector was digested with AgeI and EcoRI. Restriction 
digestion determined that there were four potential transformants that could be used for 
experimentation: three N-terminus clones and one C-terminus clone. They were purified 
and named strains MV7033, MV7034, MV7035, and MV7036. Purified plasmid DNA 
from these strains was sent to GeneWiz Boston (Cambridge, MA) for sequencing to 
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determine if the fusion contained NCOA7-AS. Primers used for sequencing were 613, 
614, 615, and 616. 
 
Lactose Papillation Plating  
To further test potential positives and to determine whether fusion to EGFP 
interfered with NCOA7-AS’s antioxidant activity, E. coli with mutations in mutM and 
mutY were transformed with the 4 clones purified in the ligation step. Wild type mutM 
and mutY prevent GC->TA transversions by repairing 8-oxoG. This strain also carries a 
lacZ gene that changes to Lac+ when GC->TA transversion mutagenesis occurs, which 
functions as a reporter of spontaneous oxidative DNA damage. For each clone, 30 μl of 
cells were combined with 20 μl of PCM buffer and 5μl of DNA on ice, the reactions were 
incubated at 37°C for 2 minutes, and then incubated at room temperature for 10 minutes. 
After this incubation, 2 ml of LB were added to each of the transformation mixes, and the 
cultures incubated in a 37°C shaker for 1 hour. All cultures were plated at 10
-5
 and 10
-6
 
dilutions on Lac+ Lactose papillation plates with Kan and incubated for 24 hours at 
37°C.   
 
Cell Lines and Culture 
 The cell lines utilized in this study were HT1080 and HeLa. HT1080 is a 
fibrosarcoma cell line created from a biopsy of a fibrosarcoma present in a 35 year old 
human male that had not undergone radiation or chemotherapy (Rasheed et al., 1974). 
HeLa cells are an immortal cell line derived from cervical cancer cells originally taken 
from a patient in 1951 (Scherer et al., 1953). The cells were cultured at 37°C in 1X 
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DMEM supplemented with 10% Fetal Bovine Serum, 4.5 g/L of glucose and L-
glutamine, in the absence of sodium pyruvate. 
 
Transfection and Fluorescence Microscopy 
Transfection of HeLa and HT1080 Cells 
 Cell lines used for transfection were split into 6 well plates, with each well 
containing 2 ml of media and cells. Cells were maintained at 50-80% confluency in 
DMEM with 10% FBS and no antibiotics. This setup was completed for both HeLa and 
HT1080 cells. For each transfection, 4 µg of DNA were diluted in 250 µl of Opti-MEM
®
 
Reduced Serum Medium, and mixed gently. Then 10 µl of Lipofectamine
TM
 was diluted 
in 250 µl of Opti-MEM
®
 and incubated at room temperature for 5 minutes. The solution 
containing the diluted DNA was then combined with that of the diluted Lipofectamine
TM
 
and incubated for 20 minutes at room temperature. Growth medium of the cells was 
removed and replaced with 2 ml of fresh medium, and the 500 µl of the DNA / 
Lipofectamine
TM
 complexes were added to each well. The cells were incubated for 3 
hours, and media was replaced after this incubation period. There were 20 transfections 
performed in total: 2 HeLa transfections containing a fluorescent control (M Cherry), 2 
HT1080 transfections containing a fluorescent control (M Cherry), 4 HeLa transfections 
containing the plasmid isolated from strain MV7034, 4 HT1080 transfections containing 
the plasmid isolated from strain MV7034, 4 HeLa transfections containing the plasmid 
isolated from strain MV7035, and 4 HT1080 transfections containing the plasmid isolated 
from strain MV7035. 
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Fluorescence Microscopy 
  All wells containing transfected cells were observed under fluorescence 
microscopy at 100X magnification to verify M. cherry (red) or GFP (green) fluorescence, 
and photographs of each transfection were taken. After observation, half of each type of 
transfection was treated with 32 µl of 50 mg/ml of G418 to ensure selection of NCOA7-
AS clones. These G418 selected transfections were incubated for 4 days, then observed 
under fluorescence microscopy at 100X magnification and photographed. The remaining 
half of the transfections were treated with 2.2 µl of a mixture of 2 µl of Interferon-β, and 
200 µl of DMEM with 10% FBS. The treated transfections were incubated for 24 hours, 
then observed under fluorescence microscopy at 100X magnification and photographed. 
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RESULTS 
 
 The overall purpose of this project was to determine the localization of NCOA7-
AS using a GFP fusion approach, and determining whether treatment of the cells with 
IFNβ-1b would alter NCOA7-AS localization. 
 
Creation of an NCOA7-AS-GFP Fusion Plasmid 
 Two PCR products were created using primers 609, 610, 611 and 612, and a stock 
plasmid sample of NCOA7-AS as the template. Primers 609 and 610 were designed to 
produce an NCOA7-AS product that had EcoRI and AgeI restriction sites to be fused to 
the N-terminus of EGFP. Primers 611 and 612 were designed to produce an NCOA7-AS 
product that had BspEI and EcoRI restriction sites to be fused to the C-terminus of EGFP.  
These PCR products, pEGFP-N1 and pEGFP-C1 were all digested using their 
corresponding restriction enzymes, then both of the digested PCR products were ligated 
into their respective pEGFP vectors, and transformed into competent DH5α. Ten total 
transformants were obtained, five with the N-terminus fusion and five with the C-
terminus fusion. To determine whether these transformants contained the NCOA7-AS 
insert, plasmid DNA was purified, restricted, and run on a 5% agarose electrophoresis gel 
(Figure 5). Analysis of the gel showed that three N-terminus fusions (circled in the 
figure) appeared to contain the NCOA7-AS insert (665 bp) (lanes 8, 9, and 10, in Figure 
5).  The inserts appeared to have the correct size, as measured against a 1kb ladder.  None 
of the C-terminus fusions appeared to contain the insert (lanes 2-6, Figure 5). 
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Figure 5: NCOA7-AS-GFP Fusions Created using Primers 609, 610, 611, and 612. Gel electrophoresis 
of purified and restricted DNA from DH5α transformants. Positive plasmid DNAs pMV1559 and 
pMV1560 were isolated from transformants MV7034 and MV7035 respectively (Lane 1: 1kb DNA ladder; 
Lane 2: EGFP-NCOA7-AS from C1 transformant 1 cut with BspEI and EcoRI; Lane 3: EGFP-NCOA7-AS 
from C1 transformant 2 cut with BspEI and EcoRI; Lane 4: EGFP-NCOA7-AS from C1 transformant 3 cut 
with BspEI and EcoRI; Lane 5: EGFP-NCOA7-AS from C1 transformant 4 cut with BspEI and EcoRI; 
Lane 6: EGFP-NCOA7-AS from C1 transformant 5 cut with BspEI and EcoRI; Lane 7: pEGFP-C1 vector 
cut with BspEI and EcoRI; Lane 8: NCOA7-AS-EGFP from N1 transformant 1 cut with EcoRI and AgeI; 
Lane 9: NCOA7-AS-EGFP from N1 transformant 2 cut with EcoRI and AgeI; Lane 10: NCOA7-AS-EGFP 
from N1 transformant 3 cut with EcoRI and AgeI; Lane 11: NCOA7-AS-EGFP from N1 transformant 4 cut 
with EcoRI and AgeI; Lane 12: NCOA7-AS-EGFP from N1 transformant 5 cut with EcoRI and AgeI; Lane 
13: pEGFP-N1 vector cut with EcoRI and AgeI) (Circled bands indicate possible presence of NCOA7-AS) 
Expected length of NCOA7-AS insert: 665bp. 
 
 
 
 To determine whether the apparently negative C-terminus fusions analyzed were 
actually the result of a partial digestion, samples of four C-terminus fusions were again 
digested and run on a 5% agarose electrophoresis gel. Analysis of this gel showed that 
only one transformant possibly contained NCOA7-AS in the fusion (lane 8 circled, 
Figure 6).  
1 2 3 4 5 6 7 8 9 10 11 12 13 
10000bp 
8000bp 
6000bp 
5000bp 
4000bp 
3000bp 
2000bp 
1000bp 
500bp 
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Figure 6: NCOA7-AS-GFP C-terminus fusions using primers 609 and 610. Gel electrophoresis of 
second digested sample of purified DNA from DH5α transformants (Lane 1-5: empty, Lane 6: 1kb DNA 
ladder, Lane 7: EGFP-NCOA7-AS from C1 transformant 1 cut with BspEI and EcoRI; Lane 8: EGFP-
NCOA7-AS from C1 transformant 3 cut with BspEI and EcoRI; Lane 9: EGFP-NCOA7-AS from C1 
transformant 4 cut with BspEI and EcoRI; Lane 10: EGFP-NCOA7-AS from C1 transformant 5 cut with 
BspEI and EcoRI) (Circled band indicates possible presence of NCOA7-AS). Expected length of NCOA7-
AS insert: 665bp. 
 
 
This C-terminal fusion plasmid, and the three N-terminus fusion plasmids, were 
sequenced by GeneWiz using primers that overlapped the beginning of the coding strand 
and end of the template strand of the expected NCOA7-AS insert. The sequencing 
confirmed the insert in two of the N-terminus fusions, which were saved as strains 
MV7034 and MV7035. 
 To again try to obtain a C-terminus fusion, DH5α cells were transformed with a 
sample of a new C-terminus ligation, as well as the remainder of the previous C-terminus 
ligation. This resulted in only two transformants from the new ligation. DNA from these 
colonies was purified, restricted, and run on a 5% agarose electrophoresis gel (data not 
shown). Analysis of the gel revealed that the insert was again not present in the C-
terminal fusion plasmid. 
1 2 3 4 5 6 7 8 9 10 
3000bp 
2000bp 
1000bp 
500bp 
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Oxidative Resistance Confirms the NCOA7-AS Insert 
 In order to determine whether the NCOA7-AS-EGFP fusion protein retained 
oxidation resistance activity, E. coli containing mutations in mutM and mutY were 
transformed with the two confirmed N-terminus fusion plasmids. As previously 
described, GC->TA transversion mutations in colonies of these cells are indicators of 
spontaneous oxidative damage, and such cells become Lac+.  MutM mutY E. coli 
transformed with one of the failed C-terminus ligations (Figure-7A) shows an elevated 
level of transversion mutations, indicating a high level of oxidative damage, as seen by 
the dark blue Lac
+
 microcolonies within the white Lac
-
 parent colonies. E. coli containing 
the sequenced, purified N-terminal plasmids (Figures 7B and 7C) shows that the 
presence either of the two vectors expressing NCOA7-AS-EGFP suppresses oxidative 
mutagenesis (fewer Lac+ colonies).  Thus, oxidation resistance activity appears to be 
contained within the expressed NCOA7-AS-EGFP protein, indicating that fusion with the 
GFP did not hinder its oxidative resistance activity, and that NCOA7-AS is present in 
both vectors. 
 
 
Figure 7: (A) MutM mutY E. coli transformed with failed NCOA7-AS-GFP C-terminus 
fusion. (B) MutM mutY E. coli transformed with purified plasmid from strain MV7034. 
(C) MutM mutY E. coli transformed with purified plasmid from strain MV7035. 
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Fluorescence Microscopy of Transfected HeLa and HT1080 Cells 
 In order to determine the subcellular localization of the NCOA7-AS fusion, HeLa 
and HT1080 cells were transfected with purified DNA from strains MV7034 and 
MV7035, and examined using fluorescence microscopy. Transfections were also treated 
with IFNβ-1b to determine whether interferon altered localization of the fusion protein. 
HeLa transfections containing the M. Cherry control show red fluorescence (Figure 8A), 
indicating the transfections worked correctly.  Observing HeLa cells transfected with 
DNA from strains MV7034 and MV7035 showed that most of the cells expressing the 
fusion protein were dead cells (Figure 8), but a few live cells were found to express the 
NCOA7-AS fusion protein as diffuse throughout the cell with no specific subcellular 
localization (Figures 8B and 8E). Stable selection of some of the transfections also 
showed the same result that most cells expressing the protein were dead, but those that 
were alive showed diffusion of the protein throughout the cell (Figures 8C and 8F). 
HeLa transfections treated with IFNβ-1b showed the same result, suggesting that 
interferon does not alter the localization of the fusion protein (Figures 8D and 8G). All 
transfections performed on HT1080 cells with purified DNA from strains MV7034 and 
MV7035 showed no expression of the fusion protein.  
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Figure 8: Fluorescence Microscopy of Transfected HeLa Cells at 100x Magnification: (A) HeLa 
transfected with M. Cherry.  Circled cells indicate live cells expressing red fluorescing M. Cherry. (B) 
HeLa transfected with purified DNA from MV7034 with no treatment. (C) HeLa transfected with purified 
DNA from MV7034 treated with G418. (D) HeLa transfected with purified DNA from MV7034 treated 
with IFNβ-1b. (E) HeLa transfected with purified DNA from MV7035 with no treatment. (F) HeLa 
transfected with purified DNA from MV7035 treated with G418. (G) HeLa transfected with purified DNA 
from MV7035 treated with IFNβ-1b. B-G: Circled cells indicate live cells expressing the NCOA7-AS-GFP 
fusion protein. 
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DISCUSSION 
 
 
 The main goal of this project was to determine where protein NCOA7-AS 
localizes within cells. This goal was accomplished by creating an NCOA7-AS-GFP 
fusion protein, transfecting it into two different human cells lines, and observing where 
the fusion protein localized in the cells using fluorescence microscopy.  
In order to determine whether the ligations resulted in the fusion of NCOA7-AS 
and EGFP genes, purified DNA from DH5α transformants was restricted to identify 
plasmids that had inserts of the appropriate size. Plasmids that appeared to have the insert 
were then sequenced to confirm in-frame fusion of the two proteins. Sequencing 
confirmed the clone construction was correct for two strains MV7034 and MV7035.  
In order to determine whether the fusion protein exhibited the antioxidant activity 
present in the normal, non-fused protein, E. coli containing mutations in mutM and mutY 
were transformed with purified DNA from strains MV7034 and MV7035. These 
transformations showed oxidative damage prevention (measured by a reduced dark blue 
LacZ+ expression and thus fewer DNA transversions).  This demonstrates that the fusion 
NCOA7-AS-EGFP proteins retained the oxidation resistance activity of normal NCOA7-
AS.  
Fluorescence microscopy examination of HeLa cells transfected with the plasmids 
showed that most of the cells expressing it were dead. However, a few live cells were 
found to express the NCOA7-AS fusion protein as diffuse green throughout the cell with 
no specific subcellular localization. This suggests that NCOA7-AS has no specific 
subcellular localization. HT1080 cells however were unable to express the fusion protein 
after transfection, so no results could be obtained from those cells. 
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 The other goal of this project was to determine whether induction of the cells with 
IFNβ-1b altered the location of the NCOA7-AS fusion protein. It was observed in HeLa 
cells treated with IFNβ-1b that the fusion protein was again diffuse throughout the cells, 
with no clear subcellular localization, which suggests that IFNβ-1b treatment does not 
alter the localization of NCOA7-AS. 
 Previous studies have determined the structure of NCOA7-AS, its function as an 
oxidative damage prevention protein, its regulation via the JAK-STAT pathway, and its 
induction by treatment with IFNβ-1b (Yu et al., submitted for publication). However, 
localization of the protein was previously undetermined. This project helps to further this 
work by suggesting that NCOA7-AS has no specific subcellular localization, based on 
the results obtained from fluorescence microscopy of the fusion protein. 
 Unfortunately some problems arose throughout the course of the project. One 
problem that occurred was the inability to produce a C-terminal fusion of NCOA7-AS 
and pEGFP. Multiple ligations were performed, but none resulted in a usable C-terminus 
fusion. A likely explanation for this is that the fusion was too unstable, and the bacterial 
cells selected the parental plasmid pEGFP against the fusion protein plasmid, removing 
the NCOA7-AS insert after ligation, thus deleting any NCOA7-AS sequences. Another 
problem was that many of the transfected HeLa cells that expressed the NCOA7-AS-
EGFP fusion protein were dead. The high number of dead cells expressing the protein 
indicates that the fusion may be toxic to the cells due to high expression of the gene 
caused by the CMV constitutive promoter in the fusion. The biggest problem that 
occurred was that HT1080 cells were unable to express the fusion protein in any of the 
transfections. Transfecting the HT1080 cells was not a problem, as they demonstrated M. 
 30 
cherry red signals equivalent to HeLa cells with the transfection marker plasmid.  The 
lack of transfection with the NCOA7-AS plasmids most likely resulted from the HT1080 
cells being more sensitive than HeLa to the toxicity of the fusion, so they could not 
successfully express it. 
 There is still much to learn about NCOA7-AS. Because the fusion of NCOA7-AS 
to a vector with a strong constitutive promoter somewhat limited the project.  For 
example, a EGFP fluorescent clone with an NCOA7-AS insert and a promoter that can be 
induced with IFNβ-1b could be created. This would allow the experimenter to control the 
level of NCOA7-AS expression, hopefully to limit its toxicity while allowing its location 
to be determined.  It would also allow a method for determining whether IFNβ alters the 
localization of NCOA7-AS. Another method of confirming localization would be to 
conduct experiments that examine the location of the endogenous protein. For example, 
immunostaining could be performed with an NCOA7-AS-specific antibody and a 
fluorescent secondary antibody to examine localization of the native protein to determine 
if it shows a similar diffuse localization as the fusion protein in this project. 
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